Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma
Clinical trial NCT07517653 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07517653
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-01
- Primary completion
- 2028-11-30
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.